

Caroline Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2991074/publications.pdf>

Version: 2024-02-01

223
papers

21,877
citations

14644

66
h-index

9579

142
g-index

229
all docs

229
docs citations

229
times ranked

14534
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
3	Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 222-233.	6.7	1,111
4	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
5	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	18.1	816
6	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
7	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
8	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006, 8, 209.	1.6	469
9	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , 2005, 7, R784-95.	1.6	425
10	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
11	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
12	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. <i>Rheumatology</i> , 2016, 55, 1693-1697.	0.9	350
13	Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis and Rheumatology</i> , 2014, 66, 369-378.	2.9	343
14	The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. <i>Arthritis and Rheumatism</i> , 1995, 38, 551-558.	6.7	328
15	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 685-708.	1.4	281
16	The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004: The Georgia Lupus Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, 357-368.	2.9	269
17	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
18	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.5	266

#	ARTICLE	IF	CITATIONS
19	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 972-979.	6.7	252
20	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	3.0	249
21	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	0.9	247
22	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.5	231
23	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994, 24, 191-195.	1.6	212
24	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	2.9	189
25	Ocular manifestations of systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 46, 1757-1762.	0.9	184
26	Adverse events and efficacy of TNF- α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009, 48, 1451-1454.	0.9	173
27	Chronic therapy with recombinant tumor necrosis factor- β in autoimmune NZB/NZW F1 mice. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 421-434.	2.1	159
28	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011, 50, 982-988.	0.9	155
29	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.5	143
30	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 211-221.	6.7	139
31	The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis and Rheumatology</i> , 2017, 69, 1996-2005.	2.9	135
32	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1. <i>Rheumatology</i> , 2016, 55, 1698-1702.	0.9	129
33	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	2.9	126
34	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	0.9	115
35	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.5	115
36	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , 2021, 73, 991-996.	2.9	114

#	ARTICLE	IF	CITATIONS
37	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2011, 50, 657-664.	0.9	112
38	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	0.9	111
39	Systemic lupus erythematosus: Clinical presentations. <i>Autoimmunity Reviews</i> , 2010, 10, 43-45.	2.5	108
40	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 231-8.	1.0	108
41	Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. <i>Rheumatology</i> , 2009, 48, 1506-1511.	0.9	107
42	Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People, 2007-2009. <i>Arthritis and Rheumatology</i> , 2014, 66, 2494-2502.	2.9	103
43	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	2.9	98
44	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.4	97
45	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
46	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 4113-4119.	6.7	96
47	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006, 55, 892-899.	6.7	95
48	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006, 54, 3300-3305.	6.7	93
49	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , 2015, 54, 836-843.	0.9	92
50	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	0.9	90
51	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
52	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	1.0	83
53	Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R120.	1.6	80
54	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , 2010, 49, 723-732.	0.9	79

#	ARTICLE	IF	CITATIONS
55	Primary Anti-Phospholipid Antibody Syndrome (APS). Survey of Ophthalmology, 2002, 47, 215-238.	1.7	78
56	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.5	78
57	Hydroxychloroquine-related retinal toxicity. Rheumatology, 2016, 55, 957-967.	0.9	77
58	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	0.9	73
59	Pregnancy and rheumatic diseases. Rheumatology, 2007, 46, 1634-1640.	0.9	72
60	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology, 2013, 52, 2292-2301.	0.9	72
61	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology, 2014, 53, 275-284.	0.9	71
62	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
63	Antinuclear Antibody-“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
64	Causes and management of infertility in systemic lupus erythematosus. Rheumatology, 2011, 50, 1551-1558.	0.9	69
65	Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis and Rheumatism, 2009, 61, 587-592.	6.7	68
66	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. Journal of Rheumatology, 2017, 44, 398.1-398.	1.0	68
67	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis and Rheumatism, 2008, 58, 1784-1788.	6.7	66
68	Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open, 2014, 4, e004081.	0.8	66
69	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology, 2014, 53, 502-511.	0.9	64
70	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Annals of Internal Medicine, 2021, 174, 1647-1657.	2.0	64
71	Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis and Rheumatism, 2007, 56, 1776-1786.	6.7	63
72	Population-based lupus registries: Advancing our epidemiologic understanding. Arthritis and Rheumatism, 2009, 61, 1462-1466.	6.7	61

#	ARTICLE	IF	CITATIONS
73	The use of alternative medical therapies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 1410-1418.	6.7	60
74	Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus â€” Fulton and DeKalb Counties, Georgia, 2002â€”2016. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 419-422.	9.0	59
75	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. <i>Arthritis and Rheumatism</i> , 2007, 57, 64-70.	6.7	58
76	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 359-379.	1.4	57
77	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
78	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	2.9	55
79	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2273-2279.	1.0	54
80	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 163-175.	1.1	52
81	Managing pregnancy in inflammatory rheumatological diseases. <i>Arthritis Research and Therapy</i> , 2011, 13, 206.	1.6	49
82	25â€”Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	1.5	49
83	Efficacy of Epratuzumab, an Antiâ€”CD</sc>22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	2.9	49
84	Interferon-Î±-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erythematosus monocytes. <i>Rheumatology</i> , 2014, 53, 2249-2258.	0.9	47
85	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 1505-1513.	1.5	45
86	Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians. <i>Rheumatology</i> , 2022, 61, 2262-2274.	0.9	45
87	In Utero Azathioprine Exposure and Increased Utilization of Special Educational Services in Children Born to Mothers With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2013, 65, 759-766.	1.5	44
88	Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 47, 334-338.	0.9	43
89	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	0.9	43
90	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42

#	ARTICLE	IF	CITATIONS
91	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
92	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.5	40
93	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	1.5	39
94	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 729-735.	0.5	39
95	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
96	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	1.5	38
97	Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , 2019, 71, 95-103.	1.5	38
98	Quality of life and economic evaluation in SLE clinical trials. <i>Lupus</i> , 1999, 8, 645-654.	0.8	37
99	B-Cell Targeted Therapies in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 85-95.	2.2	37
100	Post Hoc Analysis of the Phase II/III APRIL in SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLYS and APRIL. <i>Arthritis and Rheumatology</i> , 2017, 69, 122-130.	2.9	37
101	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
102	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , 2004, 31, 2390-4.	1.0	37
103	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 470-476.	0.5	36
104	Systemic lupus and malignancies. <i>Current Opinion in Rheumatology</i> , 2012, 24, 177-181.	2.0	36
105	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	0.9	35
106	Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 457-467.	1.4	35
107	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019, 9, e032569.	0.8	35
108	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1068-1072.	1.5	34

#	ARTICLE	IF	CITATIONS
109	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	1.0	34
110	Stratifying management of rheumatic disease for pregnancy and breastfeeding. <i>Nature Reviews Rheumatology</i> , 2019, 15, 391-402.	3.5	33
111	Mycophenolate Mofetil for Remission Induction in Severe Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2005, 100, c92-c100.	2.3	32
112	Update on systemic lupus erythematosus: autoantibodies and apoptosis. <i>Clinical Medicine</i> , 2001, 1, 10-14.	0.8	31
113	Incidence of End-stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , 2016, 68, 357-365.	1.5	31
114	Epratuzumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 245-258.	1.3	31
115	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , 2020, 72, 874-881.	1.5	31
116	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa006.	0.3	31
117	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.1-2.	0.5	31
118	Incidence and Prevalence of Systemic Lupus Erythematosus Among Arab and Chaldean Americans in Southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program. <i>American Journal of Public Health</i> , 2015, 105, e74-e79.	1.5	29
119	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , 2016, 61, 65-82.	1.7	29
120	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. <i>Rheumatology</i> , 2012, 51, 1877-1880.	0.9	28
121	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , 2014, 26, 510-519.	2.0	28
122	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	1.0	28
123	Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa037.	0.3	28
124	Challenges of ethnicity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 549-561.	1.4	27
125	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 393-396.	1.0	27
126	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27

#	ARTICLE	IF	CITATIONS
127	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
128	Systemic lupus erythematosus in women: Impact on family size. <i>Arthritis and Rheumatism</i> , 2008, 59, 1656-1660.	6.7	25
129	Systemic Lupus Erythematosus and Malignancies. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 497-506.	0.8	25
130	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	2.9	25
131	A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 3109-3110.	6.7	24
132	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , 2013, 13, 405-412.	1.7	24
133	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23
134	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , 2019, 6, e000344.	1.1	22
135	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
136	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 533-550.	0.8	22
137	The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa072.	0.3	22
138	From BILAG to BILAG-based combined lupus assessmentâ€”30 years on. <i>Rheumatology</i> , 2016, 55, 1357-1363.	0.9	21
139	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21
140	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002852.	0.8	19
141	COVID-19 and shielding: experiences of UK patients with lupus and related diseases. <i>Rheumatology Advances in Practice</i> , 2021, 5, rrab003.	0.3	18
142	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus â€” Michigan Lupus Epidemiology and Surveillance Program, 2014â€”2015. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 819-824.	9.0	18
143	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	0.9	17
144	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015, 34, 263-271.	1.0	17

#	ARTICLE	IF	CITATIONS
145	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	2.9	17
146	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 359-379.	1.4	17
147	Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. <i>Lupus Science and Medicine</i> , 2021, 8, e000614.	1.1	17
148	Refractory multisystem sarcoidosis responding to infliximab therapy. <i>Clinical Rheumatology</i> , 2012, 31, 1013-1018.	1.0	16
149	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , 2014, 1, e000034.	1.1	16
150	Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , 2021, 73, 1561-1567.	1.5	16
151	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008, 58, 1789-1795.	6.7	15
152	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	1.0	15
153	Medications in pregnancy and breastfeeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 68-76.	1.4	14
154	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	0.9	14
155	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. <i>Rheumatology</i> , 2022, 61, 4006-4015.	0.9	14
156	Novel treatments for systemic lupus erythematosus. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1256-64.	2.3	14
157	The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012, 51, 2099-2105.	0.9	13
158	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	1.5	13
159	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	0.9	12
160	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
161	“But you don’t look sick”: a qualitative analysis of the LUPUS UK online forum. <i>Rheumatology International</i> , 2021, 41, 721-732.	1.5	12
162	Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. <i>Arthritis Care and Research</i> , 2017, 69, 1271-1275.	1.5	10

#	ARTICLE	IF	CITATIONS
163	Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. <i>Musculoskeletal Care</i> , 2009, 7, 210-218.	0.6	9
164	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). <i>Arthritis Care and Research</i> , 2020, , .	1.5	9
165	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
166	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , 2014, 6, 1165-1175.	1.0	8
167	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz021.	0.3	8
168	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
169	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLEâ€”data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1474-1479.	0.9	8
170	Chilblains in immune-mediated inflammatory diseases: a review. <i>Rheumatology</i> , 2022, 61, 4631-4642.	0.9	8
171	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. <i>Drugs</i> , 1994, 47, 259-285.	4.9	7
172	Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. <i>Expert Review of Clinical Immunology</i> , 2009, 5, 27-34.	1.3	7
173	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , 2021, 60, 1480-1490.	0.9	7
174	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	2.9	7
175	Medication decision-making and adherence in lupus: patientâ€physician discordance and the impact of previous â€adverse medical experiencesâ€™. <i>Rheumatology</i> , 2022, 61, 1417-1429.	0.9	7
176	Will â€the feeling of abandonmentâ€™ remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians. <i>Rheumatology</i> , 2022, 61, 3723-3736.	0.9	6
177	Factors Involved in the Pathogenesis of Neutrophilic Vasculitis in MRL/Mp-lpr/lpr Mice: A Model for Human Microscopic Angiitis. <i>Autoimmunity</i> , 1999, 31, 133-145.	1.2	5
178	Lupus and zoster. <i>Lancet, The</i> , 2003, 362, 616.	6.3	5
179	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3262-3267.	0.9	5
180	Prescribing anti-rheumatic drugs in pregnancy and breastfeedingâ€”the British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 3565-3569.	0.9	5

#	ARTICLE	IF	CITATIONS
181	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. <i>Lupus</i> , 2021, 30, 2191-2203.	0.8	5
182	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	1.1	5
183	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , 2020, 21, 652.	0.7	4
184	Large vessel vasculitides. <i>Medicine</i> , 2006, 34, 468-471.	0.2	3
185	Mortality in SLE. , 2013, , 666-675.		3
186	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	1.5	3
187	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
188	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. <i>Lupus</i> , 2021, 30, 1492-1501.	0.8	3
189	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , 2021, 23, 203.	1.6	3
190	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 569-570.	0.5	2
191	Constitutional Symptoms and Fatigue in Systemic Lupus Erythematosus. , 2016, , 317-324.		2
192	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	0.9	2
193	The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3329-3340.	0.9	2
194	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. <i>Arthritis Care and Research</i> , 0, , .	1.5	2
195	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. <i>Rheumatology</i> , 0, , .	0.9	2
196	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: Comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , 2006, 54, 2343-2344.	6.7	1
197	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	1.6	1
198	Drugs in Rheumatic Disease During Pregnancy. , 0, , 98-113.		1

#	ARTICLE	IF	CITATIONS
199	Rheumatoid Arthritis/SLE. , 0, , 267-281.		0
200	Rheumatic Disease. , 2013, , 1415-1440.		0
201	Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care and Research, 2013, 65, 1391-1392.	1.5	0
202	Malignancies in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 275-280.	0.3	0
203	E89.â€fThe Disease-Specific Lupusqol is Sensitive to Change In Patients with Moderate or Severe Systemic Lupus Erythematosus after Treatment of a Flare. Rheumatology, 0, ,	0.9	0
204	Malignancies in Systemic Lupus Erythematosus. , 2016, , 411-415.		0
205	Obituary for Paul Bacon. Rheumatology, 2018, 57, 943-945.	0.9	0
206	CS-07â€f...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, ,		0
207	233â€fEnhancing quality improvement capacity through the British Society for Rheumatologyâ€™s multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	0.9	0
208	I061â€fCancer and lupus: what are the links and what should we be looking out for?. Rheumatology, 2019, 58, .	0.9	0
209	I082â€fTo stop or not to stop? The effect of anti-rheumatic drugs in pregnancy. Rheumatology, 2019, 58, .	0.9	0
210	I095â€fManagement of lupus in pregnancy. Rheumatology, 2019, 58, .	0.9	0
211	Constitutional symptoms and fatigue in systemic lupus erythematosus. , 2021, , 351-359.		0
212	Malignancies in systemic lupus erythematosus. , 2021, , 461-467.		0
213	Malignancy risk and screening. , 2021, , 583-598.		0
214	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	0.9	0
215	Constitutional Features of Systemic Lupus Erythematosus. , 2007, , 329-335.		0
216	Co-morbidities in Systemic Lupus Erythematosus. , 2012, , 229-249.		0

#	ARTICLE	IF	CITATIONS
217	Fertility and pregnancy in autoimmune rheumatic diseases. Indian Journal of Rheumatology, 2016, 11, 115.	0.2	0
218	1124€...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
219	1107€...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
220	1704€...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
221	FC055: Effect of Atacicept on Renal Function in SLE Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
222	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	0.9	0
223	Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 0, , .	1.7	0